Related Experiment Video
Updated: Mar 30, 2026
Organoid-Derived Epithelial Monolayer: A Clinically Relevant In Vitro Model for Intestinal Barrier Function
Published on: July 29, 2021
Highly Biomimetic Ectodermal Epithelial Organoids for Epithelial Barrier Stimulation Assays
Yiming Chen1, Yuman Li1, Chenyu Deng2
1Department of Geriatric Dentistry, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices & Beijing Key Laboratory of Biomaterials for Oral Disease, Beijing, P. R. China.
Researchers developed novel ectodermal epithelial organoids (EEOs) to improve pre-clinical toxicity testing. These organoids accurately model drug and nanomaterial effects on epithelial barriers, enhancing safety assessments.
Area of Science:
- Biomaterials Science
- Toxicology
- Regenerative Medicine
Background:
- Pre-clinical assessment of pharmaceutical and biomaterial toxicity to ectodermal epithelia is crucial but limited by inadequate screening models.
- Current models lack the physiological relevance and accuracy needed for reliable toxicity evaluation.
Purpose of the Study:
- To develop a physiologically relevant and accurate screening model for evaluating ectodermal epithelial toxicity.
- To create novel ectodermal epithelial organoids (EEOs) that recapitulate in vivo tissue complexity and improve fabrication efficiency.
Main Methods:
- Ectodermal epithelial organoids (EEOs) were fabricated using developmental patterns and downregulation of the TGF-β signaling pathway.
- EEOs were validated for their ability to model barrier components like the stratum corneum and intercellular junctions.
- The model's capacity to predict dose-dependent cytotoxicity and nanomaterial-induced damage was assessed.
Main Results:
- The novel EEOs successfully recapitulated the cellular and histological complexity of native ectodermal epithelia.
- EEOs accurately captured essential barrier components, including the stratum corneum and intercellular junctions.
- The organoids effectively modeled dose-dependent pharmaceutical cytotoxicity and identified nanomaterial-induced damage to intercellular junctions.
Conclusions:
- Ectodermal epithelial organoids (EEOs) provide a robust platform for epithelial barrier stimulation tests.
- This technology offers a more accurate method for toxicity prediction in pre-clinical assessments.
- The EEO model has the potential to accelerate the development of safer pharmaceuticals and biomaterials.
